Yet, as any seasoned trader knows, opportunity is a double-edged sword. Among the myriad exchange-traded funds (ETFs) that promise access to this fertile ground, some shine like polished gems, while others glimmer only to deceive. Let us turn our gaze, then, to two such funds-one a beacon of potential, the other a cautionary tale.
So, after a lot of deliberation (and perhaps a glass of wine), I’ve found two dividend stocks worth considering. Here they are, along with a dash of reality and a sprinkle of wry humor:
Three reasons, they tell me, to pile into XRP while it’s still trading for pocket lint. Let’s parse ’em out with the care of a man who’s seen too many get-rich-quick schemes end in a ditch.
As of this writing (which occurs somewhere between a quarterly earnings call and the heat death of the universe), the “big three” – Bitcoin, Ethereum, and XRP – have outperformed traditional indices with the effortless charm of a jazz musician improvising during an earthquake. XRP, the smallest duckling of the trio, leads with a 50% gain, which is impressive until you realize it’s probably just good at counting cryptocurrency change.
But here’s the rub: this sugar-spun dreamer boasts a market cap sweeter than Willy Wonka’s vault and nary a gummy bear’s worth of revenue to show for it. Let’s peer into the chocolate river and see if this golden goose is worth the gamble.
The crypto realm, in its present state, is a veritable gala of optimism, and investors, ever the hopeful souls, cast their gaze toward the horizon. Let us, with the precision of a well-timed waltz, examine Dogecoin’s prospects for the ensuing quinquennium.
Palantir made a name for itself in the years after 9/11, providing advanced data analytics to U.S. intelligence agencies. It built a reputation for solving complex, high-stakes problems, with the government using it to fight terrorism and later track COVID cases. The U.S. federal government remains Palantir’s largest customer, but its biggest growth engine is now the commercial sector. Because apparently, spying on terrorists wasn’t lucrative enough.
UnitedHealth, you see, has been afloat on the stormy seas of modern enterprise. A company with a market cap big enough to make a king blush, yet it’s been battered by squalls of its own making. The stock, once a stately schooner, has been reduced to a leaky rowboat-down 42% in three years, and 38% this year alone. Not a single tempest, mind you, but a whole fleet of misfortunes, like a pack of wolves howling in harmony.
Let me begin by saying this: Unity Software is the kind of stock you root for, even if its recent history makes you want to bury your head under the covers. Picture this: a company whose CEO, Matthew Bromberg, has basically declared, “We’re back!” after an ill-fated attempt to charge developers a Runtime Fee-a move so unpopular it could’ve been pulled straight from one of my own misguided life decisions.
Behold the Chrome browser, that ubiquitous sentinel present on two-thirds of the globe’s digital doorways. Its creators boast of “user experience” while engineering an ecosystem where every keystroke becomes a data point in their ever-expanding gulag of behavioral analytics. Android, that operating system cloaked in open-source virtue, now powers seven of every ten smartphones – each device a willing informant transmitting intimate dossiers to Mountain View’s labyrinthine servers.